409 Biomarker utility of placental growth factor (PlGF) for placenta previa and placenta accreta spectrum (PAS)

Placenta Accreta Spectrum (PAS) represents 1:250 cases in the United States. PAS is associated with significant maternal morbidity and mortality. Numerous centers for care of patients have been established data suggested optimal outcomes referral to a center. Current guidelines rely on historic ultrasonographical findings although less than 50% are successfully referred using these criteria. Thus, our goal was explore utility Placental Growth Factor (PlGF) as biomarker high risk previa PAS. Urine specimens were collected from suspected PAS, placenta previa, scheduled repeat cesarean sections. Quantitative analysis PlGF performed by ELISA. Expression profiles correlated analyzed diagnostic accuracy reproducibility. Specimens total 24 subjects (12 6 control). urine quantities assessed Average 6.1, 18.2, 17.6 pg/mL control, respectively (p=0.24). In addition cohort subdivided traditional pathology (accreta, increta, percreta), there no statistically difference final (p=0.67). growth factor expression may be detected distinguish between control but cannot did not discriminate among pathologies percreta). serve part developing biologic hierarchy detection tertiary care.